The Study Will Evaluate The Safety And Tolerability Of Grc 54276 As A Monotherapy, And Also In Combination With Checkpoint Inhibitors In Patients With Advanced Solid Tumours And Hodgkin
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
